Journal
BIOMEDICINE & PHARMACOTHERAPY
Volume 145, Issue -, Pages -Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2021.112406
Keywords
Rhodanine; 2-thioxo-4-thiazolidinone; Structure-Activity Relationships (SAR); Cytotoxic; Cancer; Anticancer
Funding
- International Medical University (IMU) Joint-Committee on Research Ethics [BP I-2021(08)]
Ask authors/readers for more resources
Rhodanine is a privileged scaffold in medicinal chemistry with significant potential for cancer treatment, demonstrating broad biological activities and structural diversification for effective drug discovery. Rhodanine-derived compounds have shown promising anticancer activity while maintaining low cytotoxicity, highlighting their value for future cancer drug development.
Rhodanine has been recognized as a privileged scaffold in medicinal chemistry due to its well-known ability to demonstrate a broad range of biological activities. The possibility of structural diversification has contributed to the significance of rhodanine structure in effective drug discovery and design. Many studies have confirmed the potential of rhodanine-derived compounds in the treatment of different types of cancer through the apoptosis induction mechanism. Furthermore, most of the rhodanine derivatives exhibited remarkable anticancer activity in the micromolar range while causing negligible cytotoxicity to normal cells. This review critically describes the anticancer activity profile of reported rhodanine compounds and the structure-activity relationships (SAR) to highlight the value of rhodanine as the core structure for future cancer drug development as well as to assist the researchers in rational drug design.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available